In Replay Of Avandia Ban, Saudi Arabia Is First Regulator To Withdraw Long-acting Beta Agonists As Sole Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Country's Food and Drug Authority appears to be the first regulatory agency to announce a withdrawal of long-acting beta agonists that are not combined with corticosteroids, citing evidence of a linkage to an increased risk of death from asthma-related complications.
You may also be interested in...
Korea FDA Withdraws Abbott's Meridia; Criticism Increases On Agency's Dependence On U.S. FDA For Safety
SEOUL - Korea FDA banned new prescriptions for Abbott's obesity product sibutramine while it recommended "voluntary withdrawal" of the product following similar actions in the U.S. and Europe, drawing criticism that KFDA is too reliant on foreign agencies for monitoring drug safety
Saudi Regulators Suspend Use Of Avandia; GSK Says Action Not Based On Recent Data
In a new development following recent attention brought by a U.S. Senate Finance Committee report, the Saudi Arabia Food and Drug Authority has suspended the use of GlaxoSmithKline's Avandia (rosiglitazone) for six months while a review is under way
FDA Calls For Class-Wide REMS For LABA Asthma Drugs
LABA asthma drugs are the latest group of medications to be hit with a class-wide Risk Evaluation and Mitigation Strategies requirement.